查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108367

基因編輯療法市場分析及預測（至2035年）：按類型、產品、服務、技術、應用、流程、最終用戶和階段分類

Genetic Editing Therapies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球基因編輯療法市場預計將從2025年的110億美元成長到2035年的184億美元，複合年成長率（CAGR）為16.4%。這一成長主要得益於CRISPR技術的進步、基因研究經費的增加以及對個人化醫療日益成長的需求。監管支持和成功的臨床試驗也進一步推動了市場擴張。基因編輯療法市場呈現中等程度的競爭格局，其中基於CRISPR的療法應用最為廣泛，其次是TALEN和ZFN技術。主要應用領域包括腫瘤學、罕見遺傳疾病、心血管疾病和其他遺傳性疾病。由於臨床試驗項目不斷增加、監管政策的推進以及基因編輯平台的持續進步，該市場展現出強勁的成長勢頭。市場競爭既有成熟的生技公司，也有新興的創新企業，它們都致力於提高基因編輯技術的精準性、安全性和遞送效率。策略聯盟、授權協議、研究夥伴關係和收購正在加速療法的開發，擴大臨床應用，加強產品平臺，並推動下一代基因編輯療法的商業化。

由於與傳統基因編輯平台相比，CRISPR-Cas9技術具有高精度、具成本效益和易用性等優勢，因此成為基因編輯市場中規模最大、成長最快的技術。此技術廣泛應用於基因治療研究、功能基因體學、藥物研發和農業生物技術領域。 CRISPR衍生技術的持續進步，包括鹼基編輯和先導編輯，進一步拓展了其治療潛力，同時最大限度地減少了脫靶效應。生物技術和製藥公司的積極投資，以及針對遺傳疾病和癌症的臨床試驗的不斷增加，持續推動CRISPR-Cas9技術在研究和商業應用領域的需求。

市場區隔
類型 細胞株基因編輯、體細胞基因編輯及其他
產品 CRISPR 產品、TALEN 產品、ZFN 產物、Meganucleases。
服務 基因編輯服務、客製化檢測開發、諮詢服務等。
科技 CRISPR-Cas9、TALEN、ZFN、Meganucleases酶等
目的 基因治療、細胞株工程、動物基因工程、植物性因工程等。
流程 體內基因編輯、體外基因編輯及其他
最終用戶 生技公司、製藥公司、學術和研究機構、受託研究機構及其他
步 藥物發現、臨床前研究、臨床試驗、商業化等領域。

生技公司憑藉其在創新基因療法、基因修飾細胞療法和基因修飾生物體方面的積極研發，在基因編輯市場佔了相當大的佔有率。這些公司正大力投資尖端基因編輯技術，以加速研究、提高藥物研發效率並滿足尚未滿足的醫療需求。與製藥公司、學術機構和受託研究機構（CRO）不斷拓展的合作關係，進一步增強了它們的創新能力。創業投資的增加、對基因療法監管支持的加強以及臨床研發管線的擴展，都在推動生物技術公司採用基因編輯平台，而這些正是全球市場成長的主要驅動力之一。

區域概覽

北美在基因編輯療法市場佔最大佔有率，這得益於主導地位、大量的研發投入以及眾多開發CRISPR和基因編輯平台的公司。該地區受惠於政府機構和私人投資者的優惠資助，以及完善的臨床研究基礎設施。罕見遺傳疾病和癌症的高發生率推動了對創新療法的需求。生技公司、學術機構和製藥公司之間的策略合作進一步加速了產品開發和商業化進程，而有利的監管環境也鞏固了北美的市場領導地位。

在亞太地區，由於基因組醫學投資的增加、生技產業的擴張以及醫療基礎設施的改善，基因編輯療法市場預計將經歷最快的成長。中國、日本、韓國和新加坡政府正在大力推動精準醫療計劃，並支持先進的基因研究。人們對罕見疾病的認知不斷提高、臨床試驗活動的活性化以及與國際生物技術公司合作的拓展，都在推動市場發展。隨著醫療保健支出的增加、高素質科研人才的湧現以及有利於科研的政策不斷促進創新，亞太地區已成為基因編輯療法成長最快的區域市場。

主要趨勢和促進因素

精準基因編輯技術的進步正在改變我們開發治療方法的方式。

精準基因編輯平台和體內遞送技術的快速發展是塑造基因編輯治療市場的關鍵趨勢。基於CRISPR的系統、鹼基編輯、先導編輯和表觀基因編輯的創新，使得高度標靶的基因修飾成為可能，並提高了安全性和有效性。研究人員也致力於開發先進的病毒和非病毒遞送系統，以提高治療效果並最大限度地減少脫靶效應。這些進展正在擴大基因編輯治療的應用範圍，使其涵蓋遺傳性疾病、腫瘤、罕見疾病和神經系統疾病等領域，推動治療策略朝向高度個人化的方向發展。

遺傳性疾病盛行率的上升正在推動市場成長。

遺傳疾病盛行率的上升和對根治性療法的需求日益成長，是基因編輯療法市場的主要驅動力。傳統療法通常只能緩解症狀，而無法解決根本的遺傳病因，因此，能夠提供長期療效的基因編輯解決方案需求旺盛。生物技術研究投入的增加、臨床試驗的活性化、監管機構對先進療法的支持以及研究機構與製藥公司之間合作的加強，都在加速產品開發。這些因素顯著促進了基因編輯療法在全球醫療體系中的商業化和廣泛應用。

目錄

第1章：摘要整理

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 細胞株基因編輯
    • 體細胞基因編輯
    • 其他
  • 市場規模及預測：依產品分類
    • CRISPR產品
    • TALEN產品
    • ZFN產品
    • Meganucleases
    • 其他
  • 市場規模及預測：依服務分類
    • 基因編輯服務
    • 客製化檢測開發
    • 諮詢服務
    • 其他
  • 市場規模及預測：依技術分類
    • CRISPR-Cas9
    • TALEN
    • ZFN
    • Meganucleases
    • 其他
  • 市場規模及預測：依應用領域分類
    • 基因治療
    • 細胞株工程
    • 動物基因工程
    • 植物性因工程
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 生技公司
    • 製藥公司
    • 學術和研究機構
    • 受託研究機構
    • 其他
  • 市場規模及預測：依製程分類
    • 體內基因編輯
    • 體外基因編輯
    • 其他
  • 市場規模及預測：依階段分類
    • 藥物發現
    • 臨床前
    • 臨床試驗
    • 商業化
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • CRISPR Therapeutics
  • Editas Medicine
  • Intellia Therapeutics
  • Sangamo Therapeutics
  • Beam Therapeutics
  • Precision BioSciences
  • Caribou Biosciences
  • Cellectis
  • Bluebird Bio
  • Regenxbio
  • Graphite Bio
  • Verve Therapeutics
  • Allogene Therapeutics
  • Homology Medicines
  • Poseida Therapeutics
  • LogicBio Therapeutics
  • EditForce
  • Prime Medicine
  • Mammoth Biosciences
  • eGenesis Biosciences

第9章 關於我們

簡介目錄
Product Code: GIS10967

The global Genetic Editing Therapies Market is projected to grow from $11.0 billion in 2025 to $18.4 billion by 2035, at a compound annual growth rate (CAGR) of 16.4%. Growth is driven by advancements in CRISPR technology, increased funding for genetic research, and rising demand for personalized medicine. Regulatory support and successful clinical trials further bolster market expansion. The Genetic Editing Therapies Market features a moderately consolidated competitive landscape, with CRISPR-based therapies leading adoption, followed by TALEN and ZFN technologies. Key applications include oncology, rare genetic disorders, cardiovascular diseases, and other inherited conditions. The market is experiencing strong momentum through an expanding pipeline of clinical studies, increasing regulatory progress, and continuous advancements in gene-editing platforms. Competition is driven by both established biotechnology companies and emerging innovators focused on improving editing precision, safety, and delivery technologies. Strategic collaborations, licensing agreements, research partnerships, and acquisitions are accelerating therapeutic development, expanding clinical applications, strengthening product pipelines, and supporting the commercialization of next-generation genetic editing therapies.

The CRISPR-Cas9 segment represents the largest and fastest-growing technology within the gene editing market due to its high precision, cost-effectiveness, and ease of use compared to earlier gene editing platforms. It is extensively utilized in gene therapy research, functional genomics, drug discovery, and agricultural biotechnology. Continuous advancements in CRISPR variants, including base editing and prime editing, are further expanding its therapeutic potential while minimizing off-target effects. Strong investments from biotechnology and pharmaceutical companies, along with increasing clinical trials targeting genetic disorders and cancers, continue to drive demand for CRISPR-Cas9 technologies across both research and commercial applications.

Market Segmentation
TypeGermline Gene Editing, Somatic Gene Editing, Others
ProductCRISPR Products, TALEN Products, ZFN Products, Meganucleases, Others
ServicesGene Editing Services, Custom Assay Development, Consulting Services, Others
TechnologyCRISPR-Cas9, TALEN, ZFN, Meganucleases, Others
ApplicationGene Therapy, Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Others
ProcessIn Vivo Gene Editing, Ex Vivo Gene Editing, Others
End UserBiotechnology Companies, Pharmaceutical Companies, Academic and Research Institutes, Contract Research Organizations, Others
StageDiscovery, Preclinical, Clinical Trials, Commercialization, Others

Biotechnology companies account for a significant share of the gene editing market as they actively develop innovative gene-based therapeutics, engineered cell therapies, and genetically modified organisms. These companies invest heavily in advanced gene editing technologies to accelerate research, improve drug development efficiency, and address unmet medical needs. Growing partnerships with pharmaceutical firms, academic institutions, and contract research organizations further strengthen their innovation capabilities. Rising venture capital funding, increasing regulatory support for gene therapies, and expanding clinical pipelines are encouraging biotechnology companies to adopt gene editing platforms, making them one of the primary drivers of market growth globally.

Geographical Overview

North America accounts for the largest share of the genetic editing therapies market owing to its leadership in biotechnology innovation, substantial R&D investments, and strong presence of companies developing CRISPR and gene-editing platforms. The region benefits from favorable funding from government agencies and private investors, along with advanced clinical research infrastructure. High prevalence of rare genetic disorders and cancer has increased demand for innovative therapeutic solutions. Strategic partnerships between biotechnology firms, academic institutions, and pharmaceutical companies further accelerate product development and commercialization, while supportive regulatory pathways contribute to North America's market leadership.

Asia-Pacific is expected to witness the fastest growth in the genetic editing therapies market due to increasing investments in genomic medicine, expanding biotechnology industries, and improving healthcare infrastructure. Governments across China, Japan, South Korea, and Singapore are promoting precision medicine initiatives and supporting advanced genetic research. Rising awareness of rare diseases, growing clinical trial activities, and expanding collaborations with international biotechnology companies are boosting market development. Increasing healthcare spending, skilled scientific talent, and favorable research policies continue to encourage innovation, making Asia-Pacific the fastest-growing regional market for genetic editing therapies.

Key Trends and Drivers

Advancements in Precision Gene Editing Technologies Are Reshaping Therapeutic Development:

The rapid advancement of precision gene-editing platforms and in vivo delivery technologies is a major trend shaping the genetic editing therapies market. Innovations in CRISPR-based systems, base editing, prime editing, and epigenome editing are enabling highly targeted genetic modifications with improved safety and efficiency. Researchers are also focusing on developing advanced viral and non-viral delivery systems that enhance therapeutic effectiveness while minimizing off-target effects. These developments are expanding the application of genetic editing therapies across inherited disorders, oncology, rare diseases, and neurological conditions, driving the transition toward highly personalized treatment approaches.

Growing Prevalence of Genetic Disorders Is Driving the Market Growth:

The rising prevalence of inherited genetic disorders and increasing demand for curative therapies are major drivers of the genetic editing therapies market. Conventional treatments often manage symptoms without addressing the underlying genetic causes, creating strong demand for gene-editing solutions capable of providing long-term therapeutic benefits. Growing investments in biotechnology research, expanding clinical trial activities, favorable regulatory support for advanced therapies, and increasing collaboration between research institutions and pharmaceutical companies are accelerating product development. These factors are significantly contributing to the commercialization and adoption of genetic editing therapies across global healthcare systems.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Germline Gene Editing
    • 4.1.2 Somatic Gene Editing
    • 4.1.3 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 CRISPR Products
    • 4.2.2 TALEN Products
    • 4.2.3 ZFN Products
    • 4.2.4 Meganucleases
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Gene Editing Services
    • 4.3.2 Custom Assay Development
    • 4.3.3 Consulting Services
    • 4.3.4 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR-Cas9
    • 4.4.2 TALEN
    • 4.4.3 ZFN
    • 4.4.4 Meganucleases
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Gene Therapy
    • 4.5.2 Cell Line Engineering
    • 4.5.3 Animal Genetic Engineering
    • 4.5.4 Plant Genetic Engineering
    • 4.5.5 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Biotechnology Companies
    • 4.6.2 Pharmaceutical Companies
    • 4.6.3 Academic and Research Institutes
    • 4.6.4 Contract Research Organizations
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 In Vivo Gene Editing
    • 4.7.2 Ex Vivo Gene Editing
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical
    • 4.8.3 Clinical Trials
    • 4.8.4 Commercialization
    • 4.8.5 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 CRISPR Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Editas Medicine
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Intellia Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Sangamo Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Beam Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Precision BioSciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Caribou Biosciences
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cellectis
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Bluebird Bio
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Regenxbio
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Graphite Bio
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Verve Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Allogene Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Homology Medicines
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Poseida Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 LogicBio Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 EditForce
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Prime Medicine
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Mammoth Biosciences
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 eGenesis Biosciences
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us